This network contains 24,000 providers nationwide consisting of inpatient treatment centers, outpatient treatment centers, physicians, and behavioural health specialists.
The network follows strict protocols for evaluation and treatment. The network has the ability to monitor and track prescription and lab results and then correlate them to the patient claims.
This will include treatment for patients who are addicted to opioids, stimulants, central nervous system depressants, alcohol, illicit substances, as well as other drugs both prescription and over the counter.
The programme is structured with two different program levels.
There will be a typical PPO model for the repricing of bills as well as a true managed care model. The managed care model will allow for direct referral to a Network Care Coordinator who will be able to place the patient in the appropriate treatment setting, get initial comprehensive and interim evaluations, and monitor results.
The network is contracted with aggressive discounts ranging between 50-80% OFF billed charges and can be set up based on each specific client's needs.
Additionally, the programme is designed to service the commercial group health and the workers' compensation insurance sectors.
Claims will be handled through the CoreChoice Electronic Data Interface technology. Managed care processes will utilise Mines' integrated case management protocols. The substance use disorder network will use Mines' specialty network.
Dr. Steven Gass, CEO of CoreChoice, feels that this agreement will provide a total network solution that is unmatched in the industry.
This problem is one of the most prevalent issues that we are facing and while no one knows the true number of people involved, it is surely impacting many lives and it is time to address it and work toward resolving it. This integrative approach will provide the means by which someone is finally addressing the substance abuse problem.
CoreChoice is a specialty network for radiology, interventional pain management, and medical air transportation services.
For over 37 years Mines and Associates has been a business psychology firm that provides a range of services to employers including employee assistance programmes, managed behavioural healthcare, organization-al development services, wellness programmes, behavioural risk management, disease management, PPO services, and other behavioral health programs serving a diverse portfolio of clients nationwide.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference